Suppr超能文献

贝伐珠单抗增强放疗反应。

Enhancement of radiation response with bevacizumab.

机构信息

Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA.

出版信息

J Exp Clin Cancer Res. 2012 Apr 26;31(1):37. doi: 10.1186/1756-9966-31-37.

Abstract

BACKGROUND

Vascular endothelial growth factor (VEGF) plays a critical role in tumor angiogenesis. Bevacizumab is a humanized monoclonal antibody that neutralizes VEGF. We examined the impact on radiation response by blocking VEGF signaling with bevacizumab.

METHODS

Human umbilical vein endothelial cell (HUVEC) growth inhibition and apoptosis were examined by crystal violet assay and flow cytometry, respectively. In vitro HUVEC tube formation and in vivo Matrigel assays were performed to assess the anti-angiogenic effect. Finally, a series of experiments of growth inhibition on head and neck (H&N) SCC1 and lung H226 tumor xenograft models were conducted to evaluate the impact of bevacizumab on radiation response in concurrent as well as sequential therapy.

RESULTS

The anti-angiogenic effect of bevacizumab appeared to derive not only from inhibition of endothelial cell growth (40%) but also by interfering with endothelial cell function including mobility, cell-to-cell interaction and the ability to form capillaries as reflected by tube formation. In cell culture, bevacizumab induced a 2 ~ 3 fold increase in endothelial cell apoptosis following radiation. In both SCC1 and H226 xenograft models, the concurrent administration of bevacizumab and radiation reduced tumor blood vessel formation and inhibited tumor growth compared to either modality alone. We observed a siginificant tumor reduction in mice receiving the combination of bevacizumab and radiation in comparison to mice treated with bevacizumab or radiation alone. We investigated the impact of bevacizumab and radiation treatment sequence on tumor response. In the SCC1 model, tumor response was strongest with radiation followed by bevacizumab with less sequence impact observed in the H226 model.

CONCLUSIONS

Overall, these data demonstrate enhanced tumor response when bevacizumab is combined with radiation, supporting the emerging clinical investigations that are combining anti-angiogenic therapies with radiation.

摘要

背景

血管内皮生长因子(VEGF)在肿瘤血管生成中起着关键作用。贝伐单抗是一种人源化单克隆抗体,可中和 VEGF。我们研究了通过阻断 VEGF 信号通路来影响辐射反应。

方法

通过结晶紫测定法和流式细胞术分别检测人脐静脉内皮细胞(HUVEC)的生长抑制和凋亡。进行体外 HUVEC 管形成和体内 Matrigel 测定以评估抗血管生成作用。最后,在头颈部(H&N)SCC1 和肺 H226 肿瘤异种移植模型中进行一系列生长抑制实验,以评估贝伐单抗对同期和序贯治疗中辐射反应的影响。

结果

贝伐单抗的抗血管生成作用不仅来自于对内皮细胞生长的抑制(40%),还来自于干扰内皮细胞的功能,包括运动性、细胞间相互作用和形成毛细血管的能力,这反映在管形成中。在细胞培养中,贝伐单抗在照射后可使内皮细胞凋亡增加 2~3 倍。在 SCC1 和 H226 异种移植模型中,贝伐单抗与放疗联合应用可减少肿瘤血管形成并抑制肿瘤生长,与单一治疗方式相比。与单独接受贝伐单抗或放疗的小鼠相比,接受贝伐单抗联合放疗的小鼠肿瘤明显缩小。我们研究了贝伐单抗和放疗治疗顺序对肿瘤反应的影响。在 SCC1 模型中,先放疗后贝伐单抗的肿瘤反应最强,在 H226 模型中观察到的序列影响较小。

结论

总的来说,当贝伐单抗与放疗联合应用时,肿瘤反应增强,支持将抗血管生成疗法与放疗联合应用的新兴临床研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa14/3537546/ddee40c11122/1756-9966-31-37-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验